Guidance of Patients With Asthma During Preparation and During Expedition to the Aconcagua Mountain
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A selection of asthma patients were followed during preparation to climb the Aconcagua mountain. The primary goal of this follow up was to optimize patients' asthma status. Also during expedition, these patients were daily consulted by a physician. All data obtained during preparation and expedition will now be retrospectively analyzed.
| Condition |
|---|
|
Asthma |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Retrospective |
| Official Title: | Guidance of Patients With Asthma During Preparation and During Expedition to the Aconcagua Mountain |
- To assess the type of airway inflammation evoked by exercise, hypoxia and cold air [ Time Frame: one year ] [ Designated as safety issue: No ]Sputum cells and cytokine messenger ribonucleic acid will be analyzed to determine the type of airway inflammation that is induced by several triggers (exercise, hypoxia and cold air)
- To predict the occurrence of acute mountain sickness during an expedition to the Aconcagua mountain [ Time Frame: one year ] [ Designated as safety issue: No ]
- Mean Lake Louise Score in subjects
- Number of subjects with Lake Louise Score > 5
- Mean change in daily asthma symptom score
- Mean change in Asthma control test score
- Number of participants with an acute asthma exacerbation
Biospecimen Retention: Samples With DNA
induced sputum cells and peripheral blood sample
| Enrollment: | 18 |
| Study Start Date: | January 2009 |
| Study Completion Date: | September 2012 |
| Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Asthma patients
all
|
Detailed Description:
Preparation phase:
Eighteen asthma patients were selected based on physical and medical characteristics. During the year of preparation, several time points of evaluation were planned: evaluation at baseline, maximal exercise test in hypoxia (FiO2: 11%), 24hour stay at cold air environment.
At baseline, medical history was evaluated and clinical examination, ECG, lung function, Fraction of exhaled NO measurement and histamine provocation were performed.
During a second visit, patients stayed for approximately one hour in a chamber to simulate high altitude (FiO2:11%) and performed a maximal exercise test after 30 minutes of rest. Oxygen saturation, ECG and oxygen consumption were continuously monitored. Lung function and fraction of exhaled NO were assessed before and after the test. Also, peripheral blood was drawn before and after the test. This test allowed us to identify whether patients may develop acute mountain sickness later on during expedition.
During a third visit, patients stayed for 24 hours in a indoor ski centre to practice climbing techniques, building up a tent and working with the specialized materials. Temperature at the ski piste varies between -5°C and -10°C. Lung function, fraction of exhaled NO and induced sputum was assessed before and after the stay at the ski centre.
During the expedition, clinical status, heart rate and oxygen saturation were measured daily. Also, lung function and fraction of exhaled NO were regularly measured. A screening for acute mountain sickness was performed daily. Asthmatics patients were supported by two pulmonologist. Before and after expedition, spirometry, histamine provocation and induced sputum were performed.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
asthmatics with well-controlled asthma
Inclusion Criteria:
- asthma patient
- positive histamine provocation
Exclusion Criteria:
- exacerbation during the year prior to inclusion
Contacts and Locations| Belgium | |
| UZ Leuven | |
| Leuven, Vlaams-Brabant, Belgium, 3000 | |
| Study Director: | Sven S Seys, MSc | lab of clinical immunology, O&N I Herestraat 49 - bus 811, 3000 Leuven, België |
More Information
No publications provided
| Responsible Party: | Dr. Lieven Dupont, Prof. dr., Universitaire Ziekenhuizen Leuven |
| ClinicalTrials.gov Identifier: | NCT01760928 History of Changes |
| Other Study ID Numbers: | ML9478 |
| Study First Received: | December 21, 2012 |
| Last Updated: | January 2, 2013 |
| Health Authority: | Belgium: Institutional Review Board |
Additional relevant MeSH terms:
|
Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases |
Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |
ClinicalTrials.gov processed this record on May 21, 2013